YB-1 disrupts mismatch repair complex formation, interferes with MutSα recruitment on mismatch and inhibits mismatch repair through interacting with PCNA

Oncogene

Volumn 33, Issue 43, 2014, Pages 5065-5077

  Chang, Y W ^a   Mai, R T ^a,b   Fang, W H ^c   Lin, C C ^a   Chiu, C C ^a   Wu Lee, Y H ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

genome instability; mismatch repair; MutS ; PCNA; PIP box; YB 1

Indexed keywords

CYCLINE; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; METHYLNITRONITROSOGUANIDINE; MSH2 PROTEIN, HUMAN; PROTEIN MSH2; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

BINDING SITE; CHEMISTRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; METHYLNITRONITROSOGUANIDINE; MICROSATELLITE INSTABILITY; MUTATION; MUTS HOMOLOG 2 PROTEIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; Y-BOX-BINDING PROTEIN 1;

EID: 85027945611     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.450     Document Type: Article

References (85)

1. Lu ZH, Books JT, Ley TJ. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 2005; 25: 4625–4637.
2. Evdokimova V, Ovchinnikov LP, Sorensen PH. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 2006; 5: 1143–1147.
3. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402–415.
4. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 2011; 76: 1402–1433.
5. Matsumoto K, Bay BH. Significance of the Y-box proteins in human cancers. J Mol Genet Med 2005; 1: 11–17.
6. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003; 199: 251–258.
7. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997; 417: 390–394.
8. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447–450.
9. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59: 342–346.
10. Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 2004; 32: 316–327.
11. de Souza-Pinto NC, Mason PA, Hashiguchi K, Weissman L, Tian J, Guay D et al. Novel DNA mismatch-repair activity involving YB-1 in human mitochondria. DNA Repair (Amst) 2009; 8: 704–719.
12. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005; 74: 681–710.
13. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev 2006; 106: 302–323.
14. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7: 335–346. DOI: 10.1038/nrm1907
15. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18: 85–98.
16. Soreide K. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers—ready for prime time? Tumour Biol 2007; 28: 290–300.
17. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29: 673–680.
18. Dzantiev L, Constantin N, Genschel J, Iyer RR, Burgers PM, Modrich P. A defined human system that supports bidirectional mismatch-provoked excision. Mol Cell 2004; 15: 31–41.
19. Constantin N, Dzantiev L, Kadyrov FA, Modrich P. Human mismatch repair: reconstitution of a nick-directed bidirectional reaction. J Biol Chem 2005; 280: 39752–39761.
20. Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE et al. Reconstitution of 5'-directed human mismatch repair in a purified system. Cell 2005; 122: 693–705.
21. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006; 281: 30305–30309.
22. Johnson RE, Kovvali GK, Guzder SN, Amin NS, Holm C, Habraken Y et al. Evidence for involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair. J Biol Chem 1996; 271: 27987–27990.
23. Umar A, Buermeyer AB, Simon JA, Thomas DC, Clark AB, Liskay RM et al. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 1996; 87: 65–73.
24. Chen C, Merrill BJ, Lau PJ, Holm C, Kolodner RD. Saccharomyces cerevisiae pol30 (proliferating cell nuclear antigen) mutations impair replication fidelity and mismatch repair. Mol Cell Biol 1999; 19: 7801–7815.
25. Gu L, Hong Y, McCulloch S, Watanabe H, Li GM. ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic Acids Res 1998; 26: 1173–1178.
26. Flores-Rozas H, Clark D, Kolodner RD. Proliferating cell nuclear antigen and Msh2p-Msh6p interact to form an active mispair recognition complex. Nat Genet 2000; 26: 375–378.
27. Lau PJ, Kolodner RD. Transfer of the MSH2.MSH6 complex from proliferating cell nuclear antigen to mispaired bases in DNA. J Biol Chem 2003; 278: 14–17.
28. Guo S, Presnell SR, Yuan F, Zhang Y, Gu L, Li GM. Differential requirement for proliferating cell nuclear antigen in 5′ and 3′ nick-directed excision in human mismatch repair. J Biol Chem 2004; 279: 16912–16917.
29. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLalpha in human mismatch repair. Cell 2006; 126: 297–308.
30. Masih PJ, Kunnev D, Melendy T. Mismatch repair proteins are recruited to replicating DNA through interaction with proliferating cell nuclear antigen (PCNA). Nucleic Acids Res 2008; 36: 67–75.
31. Pluciennik A, Dzantiev L, Iyer RR, Constantin N, Kadyrov FA, Modrich P. PCNA function in the activation and strand direction of MutLalpha endonuclease in mismatch repair. Proc Natl Acad Sci USA 2010; 107: 16066–16071.
32. Iyer RR, Pluciennik A, Genschel J, Tsai MS, Beese LS, Modrich P. MutLalpha and proliferating cell nuclear antigen share binding sites on MutSbeta. J Biol Chem 2010; 285: 11730–11739.
33. Montecucco A, Rossi R, Levin DS, Gary R, Park MS, Motycka TA et al. DNA ligase I is recruited to sites of DNA replication by an interaction with proliferating cell nuclear antigen: identification of a common targeting mechanism for the assembly of replication factories. EMBO J 1998; 17: 3786–3795.
34. Clark AB, Valle F, Drotschmann K, Gary RK, Kunkel TA. Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes. J Biol Chem 2000; 275: 36498–36501.
35. Lee SD, Alani E. Analysis of interactions between mismatch repair initiation factors and the replication processivity factor PCNA. J Mol Biol 2006; 355: 175–184.
36. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007; 129: 665–679.
37. Liberti SE, Andersen SD, Wang J, May A, Miron S, Perderiset M et al. Bi-directional routing of DNA mismatch repair protein human exonuclease 1 to replication foci and DNA double strand breaks. DNA Repair (Amst) 2011; 10: 73–86.
38. Shell SS, Putnam CD, Kolodner RD. The N terminus of Saccharomyces cerevisiae Msh6 is an unstructured tether to PCNA. Mol Cell 2007; 26: 565–578.
39. Valentini AM, Armentano R, Pirrelli M, Caruso ML. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006; 32: 607–618.
40. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008; 14: 2900–2908.
41. Casorelli I, Russo MT, Bignami M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem 2008; 8: 368–380.
42. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012; 12: 104–120.
43. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 2000; 462: 71–82.
44. Kunz C, Saito Y, Schar P. DNA repair in mammalian cells: mismatched repair: variations on a theme. Cell Mol Life Sci 2009; 66: 1021–1038.
45. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007; 6: 1079–1099.
46. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM et al. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996; 93: 6443–6447.
47. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004; 3: 1091–1101.
48. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006; 27: 682–692.
49. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993; 362: 652–654.
50. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90: 6424–6428.
51. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995; 82: 321–330.
52. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001; 22: 1931–1937.
53. Tomita-Mitchell A, Kat AG, Marcelino LA, Li-Sucholeiki XC, Goodluck-Griffith J, Thilly WG. Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the HPRT gene. Mutat Res 2000; 450: 125–138.
54. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997; 57: 3949–3955.
55. Fujise K, Zhang D, Liu J, Yeh ET. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 2000; 275: 39458–39465.
56. Scott M, Bonnefin P, Vieyra D, Boisvert FM, Young D, Bazett-Jones DP et al. UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J Cell Sci 2001; 114: 3455–3462.
57. Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol 1995; 5: 275–282.
58. Jascur T, Fotedar R, Greene S, Hotchkiss E, Boland CR. N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) triggers MSH2 and Cdt2 protein-dependent degradation of the cell cycle and mismatch repair (MMR) inhibitor protein p21Waf1/Cip1. J Biol Chem 2011; 286: 29531–29539.
59. Lingrel JB, Croyle ML, Woo AL, Arguello JM. Ligand binding sites of Na,K-ATPase. Acta Physiol Scand Suppl 1998; 643: 69–77.
60. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol 1998; 275: F633–F650.
61. Jorgensen PL, Pedersen PA. Structure-function relationships of Na(+), K(+), ATP, or Mg(2+) binding and energy transduction in Na,K-ATPase. Biochim Biophys Acta 2001; 1505: 57–74.
62. Hidaka M, Takagi Y, Takano TY, Sekiguchi M. PCNA-MutSalpha-mediated binding of MutLalpha to replicative DNA with mismatched bases to induce apoptosis in human cells. Nucleic Acids Res 2005; 33: 5703–5712.
63. Genschel J, Bazemore LR, Modrich P. Human exonuclease I is required for 5′ and 3′ mismatch repair. J Biol Chem 2002; 277: 13302–13311.
64. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007; 25: 1196–1208.
65. Gao Y, Fotovati A, Lee C, Wang M, Cote G, Guns E et al. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 2009; 8: 3276–3284.
66. Xie W, Yang J, Cao Y, Peng C, Ning H, Zhang F et al. Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer. Tumour Biol 2012; 33: 63–71.
67. Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One 2011; 6: e20603.
68. Martinez R, Schackert HK, Plaschke J, Baretton G, Appelt H, Schackert G. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 2004; 66: 395–403.
69. Pizzi C, Di Maio M, Daniele S, Mastranzo P, Spagnoletti I, Limite G et al. Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. Oncol Rep 2007; 17: 193–199.
70. Perez-Garcia A, Carrion-Navarro J, Bosch-Fortea M, Lazaro-Ibanez E, Prat-Acin R, Ayuso-Sacido A. Genomic instability of surgical sample and cancer-initiating cell lines from human glioblastoma. Front Biosci 2012; 17: 1469–1479.
71. Chou CH, Lee RS, Yang-Yen HF. An internal EELD domain facilitates mitochondrial targeting of Mcl-1 via a Tom70-dependent pathway. Mol Biol Cell 2006; 17: 3952–3963.
72. Huang DY, Chang ZF. Interaction of human thymidine kinase 1 with p21(Waf1). Biochem J 2001; 356: 829–834.
73. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993; 67: 5823–5832.
74. Jiricny J, Hughes M, Corman N, Rudkin BB. A human 200-kDa protein binds selectively to DNA fragments containing G.T mismatches. Proc Natl Acad Sci USA 1988; 85: 8860–8864.
75. Iaccarino I, Marra G, Palombo F, Jiricny J. hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute differently to the ATPase activity of hMutSalpha. EMBO J 1998; 17: 2677–2686.
76. You LR, Chen CM, Yeh TS, Tsai TY, Mai RT, Lin CH et al. Hepatitis C virus core protein interacts with cellular putative RNA helicase. J Virol 1999; 73: 2841–2853.
77. Christmann M, Kaina B. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem 2000; 275: 36256–36262.
78. Marsischky GT, Kolodner RD. Biochemical characterization of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 complex and mispaired bases in DNA. J Biol Chem 1999; 274: 26668–26682.
79. Mai RT, Yeh TS, Kao CF, Sun SK, Huang HH, Wu Lee YH. Hepatitis C virus core protein recruits nucleolar phosphoprotein B23 and coactivator p300 to relieve the repression effect of transcriptional factor YY1 on B23 gene expression. Oncogene 2006; 25: 448–462.
80. Huang YM, Chen SU, Goodman SD, Wu SH, Kao JT, Lee CN et al. Interaction of nick-directed DNA mismatch repair and loop repair in human cells. J Biol Chem 2004; 279: 30228–30235.
81. Holmes J Jr., Clark S, Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci USA 1990; 87: 5837–5841.
82. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749–4756.
83. Drobinskaya I, Gabbert HE, Moeslein G, Mueller W. A new method for optimizing multiplex DNA microsatellite analysis in low quality archival specimens. Anticancer Res 2005; 25: 3251–3258.
84. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319–327.
85. Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576–2580.